SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of | June | 2016 | ||
Commission File Number | 001-36458 |
Neovasc Inc. |
(Translation of registrant’s name into English) |
Suite 5138 – 13562 Maycrest Way Richmond, British Columbia, Canada V6V 2J7
|
(Address of principal executive offices) |
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F | Form 40-F | X |
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
DOCUMENTS INCLUDED AS PART OF THIS REPORT
Document | ||
1 | News Release – Neovasc Inc. Reports Results of Annual General Meeting of Shareholders | |
Document 1
Neovasc Inc. Reports Results of Annual General Meeting of Shareholders
NASDAQ: NVCN
TSX: NVC
VANCOUVER, June 15, 2016 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVC) is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held on June 15, 2016 in Vancouver, B.C. (the "Meeting").
At the Meeting, the shareholders of the Company (the "Shareholders") set the number of directors at six and re-elected board members Alexei Marko, Paul Geyer, Dr. Jane Hsiao, Steven Rubin, Dr. William O'Neill, and Doug Janzen to serve in office until the next annual meeting or until their successors are duly elected or appointed. Detailed results of the voting in respect of the election of directors are as follows:
Nominee | Votes For | % Votes For | Votes Withheld | % Votes Withheld |
Alexei Marko | 47,248,704 | 99.91% | 41,555 | 0.09% |
Paul Geyer | 47,248,704 | 99.91% | 41,555 | 0.09% |
Dr. Jane Hsiao | 42,119,905 | 89.07% | 5,170,354 | 10.93% |
Steven Rubin | 42,119,905 | 89.07% | 5,170,354 | 10.93% |
Dr. William O'Neill | 44,255,199 | 93.58% | 3,035,060 | 6.42% |
Doug Janzen | 44,301,903 | 93.68% | 2,988,356 | 6.32% |
At the Meeting, the Shareholders also re-appointed Grant Thornton LLP, Chartered Accountants as auditors of the Company (99.91% of votes cast in favour).
About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products in development include the Tiara™, for the transcatheter treatment of mitral valve disease and the Neovasc Reducer™ for the treatment of refractory angina. The Company also sells a line of advanced biological tissue products that are used as key components in third-party medical products including transcatheter heart valves. For more information, visit: www.neovasc.com.
SOURCE Neovasc Inc.
%CIK: 0001399708
For further information: Investor Relations, Neovasc Inc., Chris Clark, 604 248-4138, cclark@neovasc.com
CO: Neovasc Inc.
CNW 16:47e 15-JUN-16
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Neovasc Inc. | |||
(Registrant) | |||
Date: June 15, 2016 | By: | /s/Chris Clark | |
Name: | Chris Clark | ||
Title: | Chief Financial Officer |